IO Biotech invited to speak at BioEquity Europe 2016

May 5, 2016

IO Biotech is pleased to be invited to present at Bio€quity Europe, which this year is venued in Copenhagen. This is a much welcomed chance to elaborate on the company’s scentific findings and current research to the financial community and international business development professionals.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial